To create an alert for the Global Brand Director of Entyvio at Takeda to inform the latest development, highlighting the relevance of the news and its implications for Takeda
Cancer and role of occupational therapist in cancer Ambreen Sadaf
Introduction to oncology
Role of occupational therapy
Hazards to life due to cancer
Interventional aim to cancer
Lifestyle management
Benefits of occupational therapy in oncology
Occupational service in cancer
Interventions
Role of occupational therapy in cancer or oncology
Cancer and role of occupational therapist in cancer Ambreen Sadaf
Introduction to oncology
Role of occupational therapy
Hazards to life due to cancer
Interventional aim to cancer
Lifestyle management
Benefits of occupational therapy in oncology
Occupational service in cancer
Interventions
Role of occupational therapy in cancer or oncology
Webinar: Demystifying COVID-19 Vaccine Booster
| Demystifying vaccine booster - when and why?
| Speaker: Dr. Kalaiarasu M Peariasamy.
| More information, please visit: https://clinupcovid.mailerpage.com/resources/r1r5o3-demystifying-covid-19-vaccine-boo
Corporate Presentation TiGenix - September 2014TiGenix
This document does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company, nor shall any part of it nor the fact of its distribution form part of or be relied on in connection with any contract or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of the Company.
This document may contain forward-looking statements and estimates made by the Company, including with respect to the anticipated future performance of TiGenix and the market in which it operates. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Forward-looking statements, forecasts and estimates only speak as of the date of this document and no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based.
Webinar: Demystifying COVID-19 Vaccine Booster
| Demystifying vaccine booster - when and why?
| Speaker: Dr. Kalaiarasu M Peariasamy.
| More information, please visit: https://clinupcovid.mailerpage.com/resources/r1r5o3-demystifying-covid-19-vaccine-boo
Corporate Presentation TiGenix - September 2014TiGenix
This document does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company, nor shall any part of it nor the fact of its distribution form part of or be relied on in connection with any contract or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of the Company.
This document may contain forward-looking statements and estimates made by the Company, including with respect to the anticipated future performance of TiGenix and the market in which it operates. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Forward-looking statements, forecasts and estimates only speak as of the date of this document and no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based.
Similar to Skyrizi vs. Entyvio in Patients with Crohn's Disease (20)
TOP AND BEST GLUTE BUILDER A 606 | Fitking FitnessFitking Fitness
"Feature:
• Intelligent Ergonomically Design Glute Builder Is A Must Have For Those Looking To Target Their Gluteal Muscles And Hamstrings With Precision.
• The Ability To Adjust The Starting Position, This Machine Allows For A More Targeted Workout That Is Tailored To Your Specific Needs.
• Spacious And Supportive Cushioned Seat Provide Added Comfort And Stability During Your Workout."
Get more information visit on:- www.fitking.in
Our mail I.D:-care@fitking.in, fitking.in@gmail.com
Call us at :- 9958880790, 9870336406, 8800695917
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
For those battling kidney disease and exploring treatment options, understanding when to consider a kidney transplant is crucial. This guide aims to provide valuable insights into the circumstances under which a kidney transplant at the renowned Hiranandani Hospital may be the most appropriate course of action. By addressing the key indicators and factors involved, we hope to empower patients and their families to make informed decisions about their kidney care journey.
India Diagnostic Labs Market: Dynamics, Key Players, and Industry Projections...Kumar Satyam
According to the TechSci Research report titled “India Diagnostic Labs Market Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2019-2029,” the India Diagnostic Labs Market was valued at USD 16,471.21 million in 2023 and is projected to grow at an impressive compound annual growth rate (CAGR) of 11.55% through 2029. This significant growth can be attributed to various factors, including collaborations and partnerships among leading companies, the expansion of diagnostic chains, and increasing accessibility to diagnostic services across the country. This comprehensive report delves into the market dynamics, recent trends, drivers, competitive landscape, and benefits of the research report, providing a detailed analysis of the India Diagnostic Labs Market.
Collaborations and Partnerships
Collaborations and partnerships among leading companies play a pivotal role in driving the growth of the India Diagnostic Labs Market. These strategic alliances allow companies to merge their expertise, strengthen their market positions, and offer innovative solutions. By combining resources, companies can enhance their research and development capabilities, expand their product portfolios, and improve their distribution networks. These collaborations also facilitate the sharing of technological advancements and best practices, contributing to the overall growth of the market.
Expansion of Diagnostic Chains
The expansion of diagnostic chains is a driving force behind the growing demand for diagnostic lab services. Diagnostic chains often establish multiple laboratories and diagnostic centers in various cities and regions, including urban and rural areas. This expanded network makes diagnostic services more accessible to a larger portion of the population, addressing healthcare disparities and reaching underserved populations. The presence of diagnostic chain facilities in multiple locations within a city or region provides convenience for patients, reducing travel time and effort. A broader network of labs often leads to reduced waiting times for appointments and sample collection, ensuring that patients receive timely and efficient diagnostic services.
Rising Prevalence of Chronic Diseases
The increasing prevalence of chronic diseases is a significant driver for the demand for diagnostic lab services. Chronic conditions such as diabetes, cardiovascular diseases, and cancer require regular monitoring and diagnostic testing for effective management. The rise in chronic diseases necessitates the use of advanced diagnostic tools and technologies, driving the growth of the diagnostic labs market. Additionally, early diagnosis and timely intervention are crucial for managing chronic diseases, further boosting the demand for diagnostic lab services.
Skyrizi vs. Entyvio in Patients with Crohn's Disease
1. AbbVie presents positive topline results from the Phase-3 maintenance study (FORTIFY) showing Skyrizi SC
achieves co-primary endpoints at week-52 in patients with moderate-severe Crohn’s disease
Sources: 1. AbbVie Press Release 2. PRNewswire 3. NCT03105102 4. NCT03105128 5. NCT03104413
Skyrizi® (risankizumab): IL-23 inhibitor developed by AbbVie in partnership with BI
[02-Jun-2021] Phase-3 maintenance results show patients with Crohn's disease receiving risankizumab (Skyrizi®) achieved
endoscopic response and clinical remission at one year1,2
Endpoints Skyrizi SC (180mg)
(N=157)
Skyrizi SC (360mg)
(N=141)
Skyrizi IV (N= 164)
(Control group)
Endoscopic Response (ER)
(Primary endpoint - US Plan)
47%
(P<0.001)
47%
(P<0.001)
22%
Clinical Remission (CDAI)
(Primary endpoint - US Plan)
55%
(P<0.001)
52%
(P<0.001)
41%
Clinical Remission (SF/AP)
(Primary endpoint – OUS Plan)
46%
(P>0.005)
52%
(P<0.001)
40%
Endoscopic Remission (ER)
(Secondary endpoint - OUS)
30%
(P<0.001)
39%
(P<0.001)
13%
Deep Remission
(Secondary endpoint - OUS)
25%
(P<0.001)
29%
(P<0.001)
10%
FORTIFY Efficacy Results @ WK-52
BI – Boehringer Ingelheim, SC – Subcutaneous, IV – Intravenous, WK – Week, CDAI – Crohn’s disease activity index, SF/AP – Stool frequency/Abdominal pain, OUS – Outside US, RCT – Randomized controlled trial
Skyrizi SC (360 mg, @ every WK-8)
Met co-primary endpoints in both the US /
Outside the US (OUS) analysis plan
Nearly half of patients achieved both the
primary endpoints
FORTIFY Safety Results @ WK-52: No new safety risks were observed – nearly consistent with the known safety profile of risankizumab
Rates of serious adverse events were 12.3% and 13.4% in subjects treated with Skyrizi 180 or 360mg respectively, vs. 12.5% in control group
Skyrizi SC (180 mg, @ every WK-8)
Met co-primary endpoints in the U.S. analysis
plan, but not in the OUS analysis plan
The FORTIFY study [NCT03105102]3 evaluated two doses: 180mg and 360mg of subcutaneous (SC) Skyrizi in moderate-severe Crohn’s patients
Multi-centre, randomized, double-blind, control group, 52-week Phase 3 open-label extension study (US, EU, UK, Japan, Canada, China)
Two analysis plans for clinical remission: Crohn's disease activity index (CDAI) for the US analysis plan, and stool frequency and abdominal
pain (SA/AP) the outside of the US analysis plan — due to regulatory requirements in the different regions
2. Sources: 1. AbbVie Press Release 2. Skyrizi - Advance/Motivate 3. Skyrizi Approval 4. Entyvio SC – SmPC 5. Entyvio Website
Skyrizi SC vs. Entyvio SC: As Crohn’s Disease Maintenance Therapy
SC – Subcutaneous, WK – Week, OUS – Outside the US
Skyrizi SC shows better compliance rate as compared to Entyvio SC
Skyrizi SC (180/360mg) at every 8-weeks [once in 2-months]1 Entyvio SC (108mg) at every 2-weeks [twice in a month]4
COMPLIANCE
Skyrizi SC reported more significant clinical endpoints – with quicker onset of action as compared to Entyvio SC
Clinically significant endpoints evaluated such as Endoscopic
Response and Clinical Remission [both are primary endpoints]1
Skyrizi SC (360mg) achieved both co-primary and secondary
endpoints1
Skyrizi has faster onset of action [starts to work within 4-weeks]2
Clinical Remission was only evaluated as primary endpoint5
Secondary endpoints (Clinical Response) was not statistically
significant [52% Entyvio vs. 44.8% placebo]5
At week-6 considered to reflect early onset of action5
CLINICAL
OUTCOMES
Skyrizi SC has higher chance to get launched in the US market – before Entyvio SC
Expected approval in Q2-20223: Skyrizi SC (360 mg, @WK-8)
met co-primary endpoints in both the US / OUS analysis plan
Approved in EU, Canada, Australia; However Entyvio SC has
been rejected by the US FDA
COMMERCIAL
DATA
Skyrizi SC and Entyvio SC – both have comparable safety profile
Safety profile of both tested doses of Skyrizi SC was in-line with
prior data [no new safety risks were reported]1
Favorable safety profile with 'No-box warning‘5
SAFETY
PROFILE
Skyrizi SC Entyvio SC
Entyvio will face significant competition from AbbVie’s Skyrizi which has higher compliance, favorable
clinical outcomes with faster-onset of action, and comparable safety profile
Lead/ Superiority
Negative/ Inferiority
3. Sources: 1. Seeking Alpha
Skyrizi SC vs. Entyvio SC: Recommendations
AbbVie’s Skyrizi has competitive edge over Entyvio based on new late-phase 3 clinical data:
1.
Better compliance with Skyrizi as subcutaneous formulation is taken 'once in 2-months' whereas
Entyvio SC is prescribed 'twice in a month'
2.
Might have higher acceptance within HCPs as more significant clinical endpoints were
evaluated in Skyrizi trial (such as endoscopic response, deep remission)
3.
Skyrizi has faster onset-of-action: Quicker onset-of-action is a leading parameter for HCPs
as one-third patients were found to be non-responder to biologics
4. High probability for the US launch before Entyvio; Also AbbVie’s strong relationship
with payers to secure positive formulary positioning
“AbbVie's replacements for Humira (Skyrizi and Rinvoq) are rapidly growing and will eventually make up for the
drop in sales as generics begin to pressure Humira” [Seeking Alpha, Jun-04, 2021]1